{"id":57169,"date":"2026-02-14T16:40:04","date_gmt":"2026-02-14T08:40:04","guid":{"rendered":"https:\/\/flcube.com\/?p=57169"},"modified":"2026-02-14T16:40:05","modified_gmt":"2026-02-14T08:40:05","slug":"mabworks-obexelimab-%ce%b2-wins-nmpa-approval-as-first-domestic-nmosd-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57169","title":{"rendered":"Mabworks\u2019 Obexelimab \u03b2 Wins NMPA Approval as First Domestic NMOSD Therapy"},"content":{"rendered":"\n

Beijing Mabworks Biotech Co., Ltd.<\/strong> announced that the National Medical Products Administration (NMPA)<\/strong> has approved Obexelimab \u03b2 injection (MIL62)<\/strong>, its independently developed third-generation CD20 antibody<\/strong>, for Neuromyelitis Optica Spectrum Disorder (NMOSD)<\/strong>. The first domestically-produced drug approved for NMOSD in China<\/strong> marks a breakthrough for Mabworks’ Fc-engineered antibody platform<\/strong>, with Primary Membranous Nephropathy (PMN)<\/strong>\u2014where Obexelimab \u03b2 could become the world’s first specialized therapy<\/strong>\u2014under Priority Review and final NMPA review stage<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Beijing Mabworks Biotech Co., Ltd.<\/td><\/tr>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Asset<\/strong><\/td>Obexelimab \u03b2 (MIL62) \u2013 Third-generation CD20 antibody<\/td><\/tr>
Approved Indication<\/strong><\/td>Neuromyelitis Optica Spectrum Disorder (NMOSD)<\/td><\/tr>
Significance<\/strong><\/td>First domestically-produced NMOSD drug in China<\/strong><\/td><\/tr>
Pending Indication<\/strong><\/td>Primary Membranous Nephropathy (PMN) \u2013 NDA accepted Sept\u202f2025, Priority Review, final review stage<\/strong><\/td><\/tr>
Global Potential<\/strong><\/td>World’s first specialized PMN therapeutic<\/strong> if approved<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile & Technology Platform<\/h2>\n\n\n\n
Feature<\/th>Obexelimab \u03b2 Specification<\/th>Differentiation<\/th><\/tr><\/thead>
Class<\/strong><\/td>Third-generation CD20 monoclonal antibody<\/strong><\/td>Fc-engineered<\/strong> for enhanced antibody-dependent cellular cytotoxicity (ADCC)<\/strong><\/td><\/tr>
Mechanism<\/strong><\/td>CD20+ B-cell depletion<\/strong><\/td>Targeted immunomodulation<\/strong>; reduced autoantibody production<\/strong><\/td><\/tr>
NMOSD Rationale<\/strong><\/td>Aquaporin-4 antibody-driven disease<\/strong>; B-cell central to pathogenesis<\/strong><\/td>First-line biologic alternative<\/strong> to eculizumab (Soliris)<\/strong> and inebilizumab (UPLIZNA)<\/strong><\/td><\/tr>
PMN Rationale<\/strong><\/td>PLA2R antibody-driven kidney disease<\/strong>; B-cell depletion reduces autoantibody burden<\/strong><\/td>No approved specialized therapy globally<\/strong>; potential disease-modifying standard-of-care<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical & Regulatory Progress<\/h2>\n\n\n\n
Indication<\/th>Status<\/th>Timeline<\/th>Strategic Value<\/th><\/tr><\/thead>
NMOSD<\/strong><\/td>NMPA approved (Jan\u202f24,\u202f2026)<\/strong><\/td>Launched Q1\u202f2026<\/strong><\/td>First domestic entrant<\/strong>; orphan disease premium pricing<\/strong>; neurology specialist relationships<\/strong><\/td><\/tr>
PMN<\/strong><\/td>NDA accepted; Priority Review; final stage<\/strong><\/td>Approval anticipated H1\u202f2026<\/strong><\/td>World’s first specialized PMN drug<\/strong>; nephrology blockbuster potential<\/strong>; global partnership attractiveness<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Positioning & Market Context<\/h2>\n\n\n\n
Factor<\/th>Strategic Analysis<\/th><\/tr><\/thead>
NMOSD Market<\/strong><\/td>~50,000-100,000 patients in China<\/strong>; high disability burden<\/strong>; eculizumab\/inebilizumab expensive and imported<\/strong>; Obexelimab \u03b2 domestic manufacturing cost advantage<\/strong><\/td><\/tr>
PMN Unmet Need<\/strong><\/td>~1 million global patients<\/strong>; rituximab off-label use<\/strong> with variable response<\/strong>; no approved targeted therapy<\/strong>; Obexelimab \u03b2 first-in-class opportunity<\/strong><\/td><\/tr>
Third-Gen CD20 Differentiation<\/strong><\/td>Fc-engineering enhances B-cell depletion<\/strong> vs. rituximab (first-gen)<\/strong> and ocrelizumab\/ofatumumab (second-gen)<\/strong>; potentially superior efficacy and durability<\/strong><\/td><\/tr>
Mabworks Platform Validation<\/strong><\/td>NMOSD approval validates Fc-engineering technology<\/strong>; PMN approval would establish nephrology franchise<\/strong>; additional autoimmune indications pipeline<\/strong><\/td><\/tr>
China Biotech Innovation<\/strong><\/td>Domestic antibody drug development<\/strong>; reduced import dependence<\/strong>; policy support for Category 1 innovative biologics<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Commercial & Global Outlook<\/h2>\n\n\n\n
Priority<\/th>Execution Plan<\/th>Timeline<\/th><\/tr><\/thead>
NMOSD Launch<\/strong><\/td>Hospital neurology access; patient advocacy engagement; reimbursement negotiation<\/td>Q1-Q2\u202f2026<\/td><\/tr>
PMN Approval<\/strong><\/td>Final NMPA review; nephrology KOL preparation; global regulatory strategy<\/td>H1\u202f2026<\/td><\/tr>
NRDL Inclusion<\/strong><\/td>National Reimbursement Drug List negotiation for both indications<\/td>2026-2027<\/td><\/tr>
Global Expansion<\/strong><\/td>US\/EU IND submissions; Big Pharma partnership discussions<\/td>2026-2027<\/td><\/tr>
Pipeline Expansion<\/strong><\/td>Additional autoimmune indications (SLE, MS, ITP)<\/td>2026+<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding Obexelimab \u03b2 PMN approval timelines, commercial performance in NMOSD and PMN, and Mabworks Biotech’s global expansion strategy. Actual results may differ due to final NMPA review outcomes, competitive dynamics with Roche’s CD20 franchise, and pricing negotiations with national reimbursement programs.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Beijing Mabworks Biotech Co., Ltd. announced that the National Medical Products Administration (NMPA) has approved…<\/p>\n","protected":false},"author":1,"featured_media":57170,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[1938,15,24],"class_list":["post-57169","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-mabworks-biotech","tag-product-approvals","tag-rare-orphan-disease-drugs"],"yoast_head":"\nMabworks\u2019 Obexelimab \u03b2 Wins NMPA Approval as First Domestic NMOSD Therapy - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Beijing Mabworks Biotech Co., Ltd. announced that the National Medical Products Administration (NMPA) has approved Obexelimab \u03b2 injection (MIL62), its independently developed third-generation CD20 antibody, for Neuromyelitis Optica Spectrum Disorder (NMOSD). The first domestically-produced drug approved for NMOSD in China marks a breakthrough for Mabworks' Fc-engineered antibody platform, with Primary Membranous Nephropathy (PMN)\u2014where Obexelimab \u03b2 could become the world's first specialized therapy\u2014under Priority Review and final NMPA review stage.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57169\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mabworks\u2019 Obexelimab \u03b2 Wins NMPA Approval as First Domestic NMOSD Therapy\" \/>\n<meta property=\"og:description\" content=\"Beijing Mabworks Biotech Co., Ltd. announced that the National Medical Products Administration (NMPA) has approved Obexelimab \u03b2 injection (MIL62), its independently developed third-generation CD20 antibody, for Neuromyelitis Optica Spectrum Disorder (NMOSD). The first domestically-produced drug approved for NMOSD in China marks a breakthrough for Mabworks' Fc-engineered antibody platform, with Primary Membranous Nephropathy (PMN)\u2014where Obexelimab \u03b2 could become the world's first specialized therapy\u2014under Priority Review and final NMPA review stage.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57169\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-14T08:40:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-14T08:40:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1405.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57169#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57169\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Mabworks\u2019 Obexelimab \u03b2 Wins NMPA Approval as First Domestic NMOSD Therapy\",\"datePublished\":\"2026-02-14T08:40:04+00:00\",\"dateModified\":\"2026-02-14T08:40:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57169\"},\"wordCount\":468,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57169#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1405.webp\",\"keywords\":[\"Mabworks Biotech\",\"Product approvals\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57169#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57169\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57169\",\"name\":\"Mabworks\u2019 Obexelimab \u03b2 Wins NMPA Approval as First Domestic NMOSD Therapy - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57169#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57169#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1405.webp\",\"datePublished\":\"2026-02-14T08:40:04+00:00\",\"dateModified\":\"2026-02-14T08:40:05+00:00\",\"description\":\"Beijing Mabworks Biotech Co., Ltd. announced that the National Medical Products Administration (NMPA) has approved Obexelimab \u03b2 injection (MIL62), its independently developed third-generation CD20 antibody, for Neuromyelitis Optica Spectrum Disorder (NMOSD). The first domestically-produced drug approved for NMOSD in China marks a breakthrough for Mabworks' Fc-engineered antibody platform, with Primary Membranous Nephropathy (PMN)\u2014where Obexelimab \u03b2 could become the world's first specialized therapy\u2014under Priority Review and final NMPA review stage.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57169#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57169\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57169#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1405.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1405.webp\",\"width\":1080,\"height\":608,\"caption\":\"Mabworks\u2019 Obexelimab \u03b2 Wins NMPA Approval as First Domestic NMOSD Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57169#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mabworks\u2019 Obexelimab \u03b2 Wins NMPA Approval as First Domestic NMOSD Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mabworks\u2019 Obexelimab \u03b2 Wins NMPA Approval as First Domestic NMOSD Therapy - Insight, China's Pharmaceutical Industry","description":"Beijing Mabworks Biotech Co., Ltd. announced that the National Medical Products Administration (NMPA) has approved Obexelimab \u03b2 injection (MIL62), its independently developed third-generation CD20 antibody, for Neuromyelitis Optica Spectrum Disorder (NMOSD). The first domestically-produced drug approved for NMOSD in China marks a breakthrough for Mabworks' Fc-engineered antibody platform, with Primary Membranous Nephropathy (PMN)\u2014where Obexelimab \u03b2 could become the world's first specialized therapy\u2014under Priority Review and final NMPA review stage.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57169","og_locale":"en_US","og_type":"article","og_title":"Mabworks\u2019 Obexelimab \u03b2 Wins NMPA Approval as First Domestic NMOSD Therapy","og_description":"Beijing Mabworks Biotech Co., Ltd. announced that the National Medical Products Administration (NMPA) has approved Obexelimab \u03b2 injection (MIL62), its independently developed third-generation CD20 antibody, for Neuromyelitis Optica Spectrum Disorder (NMOSD). The first domestically-produced drug approved for NMOSD in China marks a breakthrough for Mabworks' Fc-engineered antibody platform, with Primary Membranous Nephropathy (PMN)\u2014where Obexelimab \u03b2 could become the world's first specialized therapy\u2014under Priority Review and final NMPA review stage.","og_url":"https:\/\/flcube.com\/?p=57169","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-14T08:40:04+00:00","article_modified_time":"2026-02-14T08:40:05+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1405.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57169#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57169"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Mabworks\u2019 Obexelimab \u03b2 Wins NMPA Approval as First Domestic NMOSD Therapy","datePublished":"2026-02-14T08:40:04+00:00","dateModified":"2026-02-14T08:40:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57169"},"wordCount":468,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=57169#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1405.webp","keywords":["Mabworks Biotech","Product approvals","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57169#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57169","url":"https:\/\/flcube.com\/?p=57169","name":"Mabworks\u2019 Obexelimab \u03b2 Wins NMPA Approval as First Domestic NMOSD Therapy - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=57169#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=57169#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1405.webp","datePublished":"2026-02-14T08:40:04+00:00","dateModified":"2026-02-14T08:40:05+00:00","description":"Beijing Mabworks Biotech Co., Ltd. announced that the National Medical Products Administration (NMPA) has approved Obexelimab \u03b2 injection (MIL62), its independently developed third-generation CD20 antibody, for Neuromyelitis Optica Spectrum Disorder (NMOSD). The first domestically-produced drug approved for NMOSD in China marks a breakthrough for Mabworks' Fc-engineered antibody platform, with Primary Membranous Nephropathy (PMN)\u2014where Obexelimab \u03b2 could become the world's first specialized therapy\u2014under Priority Review and final NMPA review stage.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57169#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57169"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=57169#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1405.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1405.webp","width":1080,"height":608,"caption":"Mabworks\u2019 Obexelimab \u03b2 Wins NMPA Approval as First Domestic NMOSD Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57169#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mabworks\u2019 Obexelimab \u03b2 Wins NMPA Approval as First Domestic NMOSD Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1405.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57169"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57169\/revisions"}],"predecessor-version":[{"id":57171,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57169\/revisions\/57171"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/57170"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}